AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Synthroid (levothyroxine) [legacy through FY21] by Year
Synthroid (levothyroxine) [legacy through FY21] — Worldwide reported growth YoY (%) (%)
AbbVie Synthroid (levothyroxine) [legacy through FY21]: -0.6% in FY2021, up 1.3 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2021 figure comes from
“|| Synthroid | 767 | — | 767 | (0.6) | n/a | (0.6) | (0.6) | n/a | (0.6)”
Source: Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Synthroid (levothyroxine) [legacy through FY21] — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | -0.6% | +1.3 pts | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | -1.9% | – | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
Cite this data
StockData. (2026). AbbVie Synthroid (levothyroxine) [legacy through FY21] (%), annual FY2020–FY2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/synthroid-ww-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.